Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 44Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Recurrence 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Smoldering Multiple Myeloma 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia 2Down Syndrome 2beta-Thalassemia 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thalassemia 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Plasmacytoma 1Plasmablastic Lymphoma 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1

Interventions

dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Lenalidomide 2Dexamethasone 2Calcium Dobesilate 2iberdomide 1daratumumab 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Dexamethasone × 30 days × Clear all
NCT04776395 2026-06-01

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Emory University

Phase 2 Recruiting
68 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡